Cosmo Pharmaceuticals N.V. Aandelen EO -,26
- BID
68.9
- ASK
69.1
- 453 Units162 Units
- 07/21, 16:36:27 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
4.34%
Market Cap
1.09 Bil.
P/E Ratio
0.00
Dividend Yield
1.84 %
Earnings per Share
-0.23 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 68.9 G | 0 Units |
| PRICE DETERMINATION TIME | 07/21/2026 / 04:31:32 PM | |
| DAILY VOLUME (UNITS) | 0 | |
| DAILY HIGH / LOW | 68.9 | 67.6 |
| PREV. DAY'S PRICE | 67.3 | (07/20) |
| CHANGE DAY BEFORE | +1.60 | 2.38 % |
| 52 WEEK HIGH / LOW | 137 (02/04) | 57 (08/07) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -0.31 | 8.15 | -0.23 | 0.08 | 1.22 |
DIVIDENDS PER SHARE | 2.01 | 2.01 | 2.07 | 2.08 | 2.18 |
DIVIDEND YIELD IN % | 3.83 % | 3.02 % | 1.84 % | - | - |
DIVIDEND GROWTH IN % | 96.58 % | 0.47 % | 2.61 % | - | - |
PRICE - EARNINGS RATIO | - | 8.19 | - | 831.18 | 55.68 |
PRICE - BOOK RATIO | 2.08 | 2.18 | 3.80 | - | - |
PRICE - SALES RATIO | 9.09 | 4.10 | 17.21 | - | - |
PRICE - CASH FLOW RATIO | 28.05 | 6.73 | - | - | - |
Master Data
| WKN | A2AJ68 |
| ISIN | NL0011832936 |
| SYMBOL | C43 |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | COSMO PHARMACEUT. EO-,26 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | Swiss Franc |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 16.19 Mil. |
| MARKET CAPITALISATION | 1.09 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | -1.32 % | -8.19 % | -37.10 % | -45.73 % | 4.34 % | - | - | -40.44 % |
| HIGH | 69.30 | 76.50 | 108.00 | 137.00 | 137.00 | - | - | 137.00 |
| LOW | 67.00 | 67.00 | 67.00 | 67.00 | 57.00 | - | - | 67.00 |
Dividende
pro Aktie
Company profile
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.